Telix Pharmaceuticals files European application for brain cancer imaging

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus as the company announced it has submitted a European marketing authorisation application for TLX101-Px, its brain cancer imaging agent, aiming to widen access to advanced diagnostics.

What did Telix Pharmaceuticals report?

• Submitted European marketing authorisation application (MAA) for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), a glioma imaging candidate.
• The MAA covers major European markets with France acting as the Reference Member State.
• European submission aligns with the United States FDA application, with the US submission to follow.
• TLX101-Px targets better differentiation between progressive or recurrent glioma and treatment-related changes.
• TLX101-Px potentially supports broader access to advanced brain cancer imaging in Europe for both adults and children.

What else do investors need to know?

Telix has been preparing regulatory submissions for both Europe and the United States in parallel, expediting the European application. The aim is to make TLX101-Px commercially available across key European markets, addressing a notable gap where current FET-PET imaging for glioma lacks a consistent, approved product.

The TLX101-Px diagnostic is also intended to help select and track patients in Telix’s ongoing glioblastoma therapy trials, including phase 3 studies in Europe. With no commercial alternatives widely available, Telix’s product could address an urgent clinical need and support future additional indications.

What did Telix Pharmaceuticals management say?

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said:

We see a compelling opportunity in Europe to broaden access to authorized targeted radiopharmaceuticals for brain cancer imaging and therapy, and as such this submission is an important milestone for Telix. The strategic value of this submission is particularly relevant to establishing widespread glioma imaging as part of our corresponding therapeutic development program. We have been able to utilize aspects of our FDA package to expedite the European filing, which has been submitted in accordance with a pre-defined date agreed with the regulator, with the U.S. resubmission to follow.

What’s next for Telix Pharmaceuticals?

Telix plans to progress its US regulatory submission for TLX101-Px after meeting its agreed European filing date. The company is also advancing clinical programs for both TLX101-Px and its therapeutic counterpart, TLX101-Tx, aiming to support better diagnosis and treatment options for brain cancer.

If approved, TLX101-Px (proposed brand name Pixlumi®) would be the first widely commercialised FET-PET product for glioma imaging in Europe, potentially improving outcomes for thousands of patients and aligning with Telix’s broader oncology strategy.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix shares have declined 68%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.

View Original Announcement

The post Telix Pharmaceuticals files European application for brain cancer imaging appeared first on The Motley Fool Australia.

More reading

• TechnologyOne upgrades earnings guidance on AI and SaaS+ momentum
• These 2 ASX healthcare shares could jump well over 80%
• SGH Ltd confirms $32.35 per share BlueScope bid
• The Lottery Corporation posts steady earnings and dividend for 1H26
• Are these ASX shares too cheap to pass up?

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.